Farmaceutisch concern · Japan
Otsuka
Een concern van 23 bedrijven met 233 geneesmiddelen in 8 landen.
Concernstructuur
23 bedrijven in 10 landen
Laden…
Farmaceutisch concern · Japan
Een concern van 23 bedrijven met 233 geneesmiddelen in 8 landen.
23 bedrijven in 10 landen
Eén gratis account voor de Prognia-apps: Ward om te studeren, Osler voor klinische antwoorden met hun bronnen, en het netwerk om je collega’s te vinden.
Prognia stelt concerns samen uit de namen die toezichthouders publiceren en uit koppelingen tussen bedrijven; het is geen officiële concernstructuur.
Alle geneesmiddelen van alle bedrijven in het concern, actuele eerst.
1–25 van 233
| Geneesmiddel | Werkzame stof | Land | Status | Toelating |
|---|---|---|---|---|
| Abilify | Aripiprazole | EU (EMA) | Toegelaten | 2004 |
| ABILIFY2 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Aripiprazole | Verenigde Staten | Niet in de handel | 2004 |
| ABILIFY10 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY15 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 30MG **Federal Register d · Tablet, orally disintegrating | Aripiprazole | Verenigde Staten | Niet in de handel | 2006 |
| ABILIFY30 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY5 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY20 mg · Tablet | Aripiprazole | Canada | In de handel | 2009 |
| ABILIFY10mg | 15mg | 20mg | 2mg | 30mg | 5mg · Tablet | Aripiprazole | Verenigde Staten | In de handel | 2002 |
| ABILIFY9.75mg/1.3ml (7.5mg/ml) · Injectable | Aripiprazole | Verenigde Staten | Niet in de handel | 2006 |
| Abilify 1 mg/ml, drankDrank | Aripiprazole | Nederland | Toegelaten | 2005 |
| ABILIFY 1 MG/ML SOLUCION ORAL1 mg · Solución oral | Aripiprazole | Spanje | Toegelaten | 2005 |
| ABILIFY 1 MG/ML SOLUCION ORAL1 mg · Solución oral | Aripiprazole | Spanje | In de handel | 2005 |
| ABILIFY 1 mg/ml SOLUCION ORAL1 mg · Solución oral | Aripiprazole | Spanje | Toegelaten | 2005 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2019 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2004 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | Toegelaten | 2026 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2024 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2020 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2018 |
| ABILIFY 10 MG COMPRIMIDOS10 mg · Comprimido | Aripiprazole | Spanje | In de handel | 2018 |
| ABILIFY 10 mg COMPRIMIDOS BUCODISPERSABLES10 mg · Comprimido bucodispersable | Aripiprazole | Spanje | In de handel | 2020 |
| ABILIFY 10 mg COMPRIMIDOS BUCODISPERSABLES10 mg · Comprimido bucodispersable | Aripiprazole | Spanje | In de handel | 2005 |
| Abilify 10 mg, orodispergeerbare tablettenOrodispergeerbare tablet | Aripiprazole | Nederland | Toegelaten | 2005 |
Waar het geneesmiddelen registreert of maakt, en hoeveel daarvan actueel zijn.
| Land | Geneesmiddelen | Actueel | Vroeger | Bedrijven |
|---|---|---|---|---|
| Spanje | 62 | 62 | 0 | BedrijvenAlle geneesmiddelen |
| Verenigde Staten | 61 | 61 | 0 | BedrijvenAlle geneesmiddelen |
| Nederland | 32 | 32 | 0 | BedrijvenAlle geneesmiddelen |
| Canada | 31 | 27 | 4 | BedrijvenAlle geneesmiddelen |
| Singapore | 20 | 20 | 0 | BedrijvenAlle geneesmiddelen |
| Europese Unie (EMA) | 11 | 9 | 2 | BedrijvenAlle geneesmiddelen |
| Roemenië | 9 | 0 | 9 | BedrijvenAlle geneesmiddelen |
| Saoedi-Arabië | 7 | 7 | 0 | BedrijvenAlle geneesmiddelen |
Ook geregistreerd in: Australië, Brazilië, Colombia, Duitsland, Frankrijk, Italië, Maleisië, Verenigd Koninkrijk, Zweden
De ATC-groepen waartoe de meeste van zijn geneesmiddelen behoren, grootste eerst.
De werkzame stoffen in de meeste van zijn geneesmiddelen.
Hoe de registers de naam schrijven, genormaliseerd: zonder rechtsvorm, accenten en hoofdletters.
Samengesteld door Prognia uit de openbare geneesmiddelen- en bedrijfsregisters hieronder. Logo’s worden niet gebruikt.
Prognia stelt concerns samen uit de namen die toezichthouders publiceren en uit koppelingen tussen bedrijven; het is geen officiële concernstructuur.
Source: European Medicines Agency (EPAR data).
Licentie: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licentie: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licentie: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licentie: Licence Ouverte v1.0
ASIC,ASIC - Company Dataset,declared13October2026 extract,CC BY3.0 Australia,https://data.gov.au/data/dataset/asic-companies. Normalized and independently classified by Prognia;no endorsement.
Licentie: Creative Commons Attribution 3.0 Australia
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licentie: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licentie: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licentie: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos, dataset vwwf-4ftk, rowsUpdatedAt 1792152641, acquired 2026-10-26; original values retained.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Bundesinstitut für Arzneimittel und Medizinprodukte, pediatric list, acquired 2026-10-29T14:36:58.614273+00:00
Licentie: commercial redistribution permission not established
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licentie: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licentie: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licentie: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licentie: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licentie: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licentie: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licentie: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licentie: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licentie: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licentie: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Meld een fout of vraag verwijdering aanCorrecties van het bedrijf zelf zijn welkom.
Houd de geneesmiddelen van Otsuka op Prognia juist, zie hoe zorgprofessionals ze gebruiken en beantwoord wat ze vragen. Een gesprek van 20 minuten, in het Engels.
Plan een gesprekBekende farmaceutische concerns, elk met al zijn bedrijven.
Gerangschikt naar hun aantal geneesmiddelen.